During the third period, cT0-1 rates increased significantly during years 2018-2021 (122/515: 23.7%), in comparison with years 2015-2017: (57/331: 17.2%); p=0.015) for all tumor subtypes, and for HER2-positive/ER-negative (21.4%: 18/84 versus 14.0%: 6/43), Luminal B HER2-positive (25.4% (31/122) versus 17.9% (10/56)), triple-negative tumors (22.5% (43/191) versus 15.1% (19/126)) [23.2% (92/397) versus 15.6% (35/225); p=0.014, considering together these three last subtypes]. This evidence concerns the gene ERBB2 and neoplasm.